ProShares Ultra NASDAQ Biotechnology
BIB
BIB
34 hedge funds and large institutions have $25.3M invested in ProShares Ultra NASDAQ Biotechnology in 2020 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
1.45% more ownership
Funds ownership: 9.01% → 10.46% (+1.5%)
56% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 9
Holders
34
Holding in Top 10
–
Calls
$8.66M
Puts
$5.47M
Top Buyers
| 1 | +$8.34M | |
| 2 | +$1.3M | |
| 3 | +$259K | |
| 4 |
SIA
Soltis Investment Advisors
St. George,
Utah
|
+$237K |
| 5 |
Jane Street
New York
|
+$221K |
Top Sellers
| 1 | -$3.47M | |
| 2 | -$2.89M | |
| 3 | -$958K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$359K |
| 5 |
PGCM
Prescott Group Capital Management
Tulsa,
Oklahoma
|
-$210K |